Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03891784 · ClinicalTrials.gov registry record · Phase 2

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

A Phase 2 study of Pancreatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Neoplasm, sponsored by University of Washington.

Active
Registry status
Phase 2
Development phase
20
Enrollment target
2
Study locations

NCT03891784 is a Phase 2 study of Pancreatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Neoplasm that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 20 participants, below the 118-participant average among 7 other Pancreatic Neuroendocrine Tumor trials with a reported enrollment target (83% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03891784, a Phase 2 study of Pancreatic Neuroendocrine Tumor and Metastatic Digestive System Neuroendocrine Neoplasm, is active but no longer recruiting, sponsored by University of Washington.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Pancreatic Neuroendocrine Tumor Metastatic Digestive System Neuroendocrine Neoplasm Digestive System Neuroendocrine Tumor Foregut Neuroendocrine Tumor Hindgut Neuroendocrine Tumor Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm Advanced Digestive System Neuroendocrine Neoplasm Midgut Neuroendocrine Tumor Refractory Digestive System Neuroendocrine Neoplasm

Interventions

  • DRUG Abemaciclib

Study Locations (2)

Colorado

  • University of Colorado - Denver

Washington

  • Fred Hutch/University of Washington Cancer Consortium - Seattle

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2019-10-31
Est. Completion 2026-07
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03891784

The ClinicalTrials.gov registry entry for NCT03891784 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 118-participant average among 7 other Pancreatic Neuroendocrine Tumor trials with a reported enrollment target (83% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Pancreatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib is the first listed.

NCT03891784 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Colorado, Washington.

Frequently Asked Questions

What is clinical trial NCT03891784 about?

NCT03891784 is a clinical study titled "Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors". This phase II trial studies how well abemaciclib works in treating patients with digestive system neuroendocrine tumors that have spread to other places in the body, do not respond to treatment, and cannot be removed by surgery. Abemaciclib may stop the growth of tumor cells by blocking some of the ...

What is the current status of trial NCT03891784?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2019-10-31. Estimated completion is 2026-07.

What conditions does trial NCT03891784 study?

This clinical trial studies the following conditions: Pancreatic Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor, Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor.

What interventions are being tested in trial NCT03891784?

The interventions under investigation include: Abemaciclib (DRUG).

Who is sponsoring clinical trial NCT03891784?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03891784 being conducted?

This trial has 2 study locations across Colorado, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Neuroendocrine Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Neuroendocrine Tumor

All registered trials for this condition

Metastatic Digestive System Neuroendocrine Neoplasm

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.